Charles River Laboratories International, Inc. (NYSE:CRL) – Investment analysts at Gabelli lowered their FY2018 EPS estimates for shares of Charles River Laboratories International in a research note issued on Friday. Gabelli analyst S. Wojda now expects that the company will post earnings of $5.45 per share for the year, down from their prior forecast of $5.50. Gabelli also issued estimates for Charles River Laboratories International’s FY2019 earnings at $5.90 EPS, FY2020 earnings at $6.30 EPS and FY2021 earnings at $6.80 EPS.

Other equities analysts also recently issued reports about the stock. Bank of America Corporation dropped their target price on shares of Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a research note on Tuesday, October 24th. Jefferies Group LLC restated a “buy” rating and issued a $120.00 target price on shares of Charles River Laboratories International in a research note on Tuesday, September 12th. Robert W. Baird restated a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a research note on Friday, September 1st. Finally, BidaskClub downgraded shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Charles River Laboratories International has a consensus rating of “Buy” and a consensus target price of C$105.77.

ILLEGAL ACTIVITY NOTICE: This piece was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.dailypolitical.com/2017/11/13/charles-river-laboratories-international-inc-crl-to-post-fy2018-earnings-of-5-45-per-share-gabelli-forecasts.html.

Charles River Laboratories International (NYSE CRL) opened at C$102.12 on Monday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62. The company has a market cap of $4,836.56, a PE ratio of 20.06, a price-to-earnings-growth ratio of 1.63 and a beta of 0.94. Charles River Laboratories International has a one year low of C$69.51 and a one year high of C$119.05.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, November 9th. The company reported C$1.30 EPS for the quarter, topping the Zacks’ consensus estimate of C$1.22 by C$0.08. The business had revenue of C$464.23 million for the quarter, compared to the consensus estimate of C$458.93 million. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.18 EPS.

In other Charles River Laboratories International news, insider Davide Molho sold 5,982 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of C$107.55, for a total value of C$643,364.10. Following the completion of the sale, the insider now directly owns 22,714 shares in the company, valued at C$2,442,890.70. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider William D. Barbo sold 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of C$99.91, for a total transaction of C$399,640.00. Following the completion of the sale, the insider now owns 20,424 shares of the company’s stock, valued at C$2,040,561.84. The disclosure for this sale can be found here. Over the last quarter, insiders have bought 10,500 shares of company stock worth $2,885 and have sold 16,147 shares worth $1,721,154. 2.20% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in CRL. YorkBridge Wealth Partners LLC boosted its stake in Charles River Laboratories International by 445.5% in the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the company’s stock valued at $118,000 after acquiring an additional 891 shares in the last quarter. Advisor Group Inc. boosted its stake in Charles River Laboratories International by 159.4% in the third quarter. Advisor Group Inc. now owns 1,538 shares of the company’s stock valued at $165,000 after acquiring an additional 945 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the company’s stock valued at $181,000 after acquiring an additional 202 shares in the last quarter. Riverhead Capital Management LLC boosted its stake in Charles River Laboratories International by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the company’s stock valued at $195,000 after acquiring an additional 247 shares in the last quarter. Finally, Cambridge Advisors Inc. acquired a new stake in Charles River Laboratories International in the second quarter valued at approximately $202,000. Institutional investors own 97.46% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.